title: [Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update].
abstract: Disorders of lipid metabolism play a major role in the development and progression of coronary artery disease. Dyslipidemia therefore plays a central role in therapeutic approaches for prevention and treatment of cardiovascular events associated with coronary artery disease. Epidemiological studies have shown an association between various lipid metabolism parameters, the risk of developing coronary artery disease and progression of a pre-existing disease. In particular, increased levels of low-density lipoprotein cholesterol (LDL-C), reduced levels of HDL cholesterol (HDL-C), as well as high levels of triglycerides and increased lipoprotein(a) [Lp(a)] levels can be taken into account when assessing the risk stratification of patients for primary prevention of coronary artery disease. Lifestyle and dietary changes, intensified statin therapy and possibly the addition of ezetimibe remain the major interventions in both primary and secondary prevention of coronary artery disease, as they improve the prognosis particularly by lowering levels of LDL-C. Recently, genetic studies have contributed to extending our understanding of the relationship between lipid metabolism and coronary artery disease. A causal role for progression of coronary artery disease could be demonstrated for LDL-C, Lpa and triglyceride-rich lipoproteins (TRL), which could not be demonstrated for HDL-C in various studies. Furthermore, the effect of reduction of LDL-C by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and by the cholesteryl ester transfer protein (CETP) inhibitor anacetrapib on cardiovascular events is currently being investigated in large clinical outcome study programs.
authors.affiliation: Klinik für Kardiologie, Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Hindenburgdamm 30, 12203, Berlin, Deutschland.
authors.forename: D
authors.initials: D
authors.lastname: Sinning
authors.affiliation: Klinik für Kardiologie, Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Hindenburgdamm 30, 12203, Berlin, Deutschland.|Berlin Institute of Health (BIH), Berlin, Deutschland.|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland.
authors.forename: D M
authors.initials: DM
authors.lastname: Leistner
authors.affiliation: Klinik für Kardiologie, Charité - Universitätsmedizin Berlin (Campus Benjamin Franklin), Hindenburgdamm 30, 12203, Berlin, Deutschland. ulf.landmesser@charite.de.|Berlin Institute of Health (BIH), Berlin, Deutschland. ulf.landmesser@charite.de.|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Berlin, Deutschland. ulf.landmesser@charite.de.
authors.forename: U
authors.initials: U
authors.lastname: Landmesser
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000097:blood* / Q000453:epidemiology* / Q000517:prevention & control; D018450:Disease Progression; D019317:Evidence-Based Medicine; D006801:Humans; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood*; D000091362:PCSK9 Inhibitors; D015995:Prevalence; D000071449:Proprotein Convertase 9 / Q000097:blood*; D015203:Reproducibility of Results; D012307:Risk Factors; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008055:Lipids; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9
keywords: Coronary artery disease; Lipid metabolism; Lipoprotein(a); Proprotein covertase subtilisin-kexin type 9, human; Triglycerides